XENE Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its products portfolio includes Glybera, TV-45070.

$27.44  -0.75 (-2.66%)
As of 11/26/2021 13:00:00 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  Canada
IPO date:  11/05/2014
Outstanding shares:  51,589,279
Average volume:  535,621
Market cap:   $1,454,301,775
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    98420N105
ISIN:        CA98420N1050
Sedol:      BRJ3GY4
Valuation   (See tab for details)
PE ratio:   -22.12
PB ratio:   4.71
PS ratio:   73.26
Return on equity:   -26.37%
Net income %:   -330.69%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy